

Daily Research Report



Dt.: 22 Sep, 2026

INDEX	NIFTY	BANKNIFTY	USDINR
Outlook	Neutral	Neutral	Neutral

INSTITUTIONAL TRADING ACTIVITY IN CRS.			
Category	Buy Value	Sell Value	Net Value
FII	10637.17	11213.17	-576.20
DII	14098.64	11310.17	+2797.20

TRADE STATISTICS FOR 21/09/2026			
Instrument	No. of Contracts	Turnover (Cr.)	Put Call Ratio
Index Fut.	54340	8558.51	
Stock Fut.	905748	58618.09	
Index Opt.	114542464	17465437	0.93
Stock Opt.	8065843	548195.5	
F&O Total	123568395	18080809	



PIVOT TABLE					
	R2	R1	PIVOT	S1	S2
NIFTY	23559	23484	23398	23330	23246
BANKNIFTY	56863	56664	56469	56272	56076

NIFTY FUT.			
	TRIGGER	T1	T2
Above	23550	23710	23895
Below	23180	23022	22857

BANK NIFTY FUT.			
	TRIGGER	T1	T2
Above	57000	58050	58672
Below	56000	55654	55278



Nifty has extended its recovery for the fourth consecutive session following the formation of an Inside Bar near broadening-pattern support, indicating sustained efforts to stabilise, with 23110 emerging as immediate support. A close above 23340 has triggered a potential short-squeeze rally towards 23630–23700 (20-DEMA). Daily RSI continues to rebound from the oversold zone, while ADX has started declining, suggesting that the prevailing downtrend may be losing momentum. A sustained breakout above 23520 would further strengthen the case for a meaningful trend reversal towards 23700, while 24000 remains the major hurdle for the month. On the derivatives front, 23500 and 23700 remain key weekly resistance levels based on OI buildup, while a decisive move above the 23300 Call OI cluster could trigger intense short-covering momentum. On the downside, 23000 remains the key support, while a decisive break below 23100 would invalidate the recent stabilisation pattern and could accelerate the decline towards 22880. Until Nifty decisively reclaims 24050, traders should continue to favour stock-specific opportunities with disciplined risk management.

Trade Scanner: ALKEM, APOLLOHOSP, AUROPHARMA, AXISBANK, BANDHANBNK, DRREDDY, ICICIPRULI, INDIGO, JINDALSTEL, LAURUSLABS, PATANJALI, TORNTPHARM, VBL. ANGELONE, ADANIENSOL, BDL, MOTILALOFS, OFSS, SWIGGY.

RESEARCH DESK: Sacchitanand Uttekar - VP - Research (Derivatives & Technicals)

Disclaimer: Investments in securities market are subject to market risk, read all the related documents carefully before investing. The securities quoted are for illustration only and are not recommendatory | Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Disclaimer: This document is for private circulation and information purpose only and should not be regarded as an investment, trading, taxation? legal or price? risk management advice. In no circumstances it is considered as an offer to sale or a solicitation of any offer to buy or sell the Equity derivatives mentioned herein. We and our affiliates, group? companies, directors and employees, and directors and employees of our affiliates and group? companies, including persons involved in the preparation or issuance of this material may (a) have positions in Equity (derivatives or physical) mentioned hereby or (b) have other positions which might have conflicting interest with respect to any related information. The information contained hereby may have been taken from sources which we believe are reliable. We do not guarantee that such information is accurate or complete and it should not be relied upon as such. Any opinion expressed reflects judgments at this date and are subject to change without notice. Risk of loss in Equity derivatives trading can be substantial. Persons trading in Equity Derivatives should consider the suitability of trading based upon their resources, risk appetite and other relevant information; and understand that statements regarding future prospects may not be realized.